Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones - PubMed (original) (raw)
doi: 10.1038/nm.2332. Epub 2011 May 1.
David A Sarruf, Saswata Talukdar, Shweta Sharma, Pingping Li, Gautam Bandyopadhyay, Sarah Nalbandian, WuQiang Fan, Jiaur R Gayen, Sushil K Mahata, Nicholas J Webster, Michael W Schwartz, Jerrold M Olefsky
Affiliations
- PMID: 21532596
- PMCID: PMC3380629
- DOI: 10.1038/nm.2332
Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones
Min Lu et al. Nat Med. 2011 May.
Abstract
In adipose tissue, muscle, liver and macrophages, signaling by the nuclear receptor peroxisome proliferator-activated receptor-γ (PPAR-γ) is a determinant of insulin sensitivity and this receptor mediates the insulin-sensitizing effects of thiazolidinediones (TZDs). As PPAR-γ is also expressed in neurons, we generated mice with neuron-specific Pparg knockout (Pparg brain knockout (BKO)) to determine whether neuronal PPAR-γ signaling contributes to either weight gain or insulin sensitivity. During high-fat diet (HFD) feeding, food intake was reduced and energy expenditure increased in Pparg-BKO mice compared to Pparg(f/f) mice, resulting in reduced weight gain. Pparg-BKO mice also responded better to leptin administration than Pparg(f/f) mice. When treated with the TZD rosiglitazone, Pparg-BKO mice were resistant to rosiglitazone-induced hyperphagia and weight gain and, relative to rosiglitazone-treated Pparg(f/f) mice, experienced only a marginal improvement in glucose metabolism. Hyperinsulinemic euglycemic clamp studies showed that the increase in hepatic insulin sensitivity induced by rosiglitazone treatment during HFD feeding was completely abolished in Pparg-BKO mice, an effect associated with the failure of rosiglitazone to improve liver insulin receptor signal transduction. We conclude that excess weight gain induced by HFD feeding depends in part on the effect of neuronal PPAR-γ signaling to limit thermogenesis and increase food intake. Neuronal PPAR-γ signaling is also required for the hepatic insulin sensitizing effects of TZDs.
Figures
Fig. 1. Neuronal deletion of Pparγ in brain knockout mice
(a) Quantification of wild type Pparγ mRNA in various brain regions of Pparγ f/f mice and BKO mice. Data shown are the fold induction of gene expression normalized with housekeeping gene and expressed as mean ± SEM. (b) RT–PCR showing wild type and mutant (KO) Pparγ mRNA in various tissues in control and BKO mice. (c) Quantification of tissue Pparγ mRNA expression. Data shown are the fold induction of gene expression normalized with housekeeping gene and expressed as mean ± SEM. Asterisks indicate statistical significance (p < 0.05) between conditions connected by bars.
Fig. 2. Energy balance parameters in Pparγ brain KO mice
(a) Body weight of _Pparγ_–f/f and BKO mice on either standard chow or HFD. Dagger indicates statistical significance (p < 0.01) between genotypes. (b) Body composition analysis of control (n = 8) and Pparγ BKO (n = 6) mice at wk 5 on HFD. (c) Ambulatory activity of control (n = 7) and BKO (n = 6) mice at wk 6 on HFD. (d) Average 24–h energy expenditure in control (n = 8) and BKO (n = 6) mice after adjustment for body size differences and 24–h average activity. (e) Weekly caloric intake of control (n = 12) and BKO (n = 11) mice at weeks 1 and 12 on HFD. (f) Serum leptin concentration in control and BKO mice fed either standard chow or HFD (n = 5–9 per group). (g) Western blot showing acute leptin–stimulated phosphorylation of STAT3 (Y705) in hypothalamus. Data shown are quantified ratio of p–STAT3/total STAT3 normalized to vehicle group. All data are mean ± SEM. Statistical significance between control and Pparγ BKO mice, or between conditions connected by bars, is indicated by asterisks (p < 0.05), daggers (p < 0.01), double daggers (p < 0.001), or NS (not significant).
Fig. 3. Effect of rosiglitazone on weight gain and food intake in control and Pparγ BKO mice
(a) Rosiglitazone–induced weight gain in _Pparγ_f/f (n = 14), Syn–Cre (n = 6), and Pparγ BKO (n = 11) mice. Age of mice, start time of HFD, and HFD + rosiglitazone (rosi) are indicated. (b) Body weight gain of control and Pparγ BKO mice that were fed HFD for 16 wk followed by HFD with or without rosiglitazone treatment. Data are shown for weeks 28–34 (n = 6–14 per group). (c) Weekly caloric intake before and after rosiglitazone treatment in HFD-fed mice showing the effect of rosiglitazone on food intake in control (n = 14) and Pparγ BKO (n = 11) mice. (d) Measurement of Ucp1 mRNA in epididymal white adipose tissue from control and Pparγ BKO mice. (e) BAT Ucp1 mRNA expression in control and Pparγ BKO mice after rosiglitazone treatment. (f) Histochemical image of BAT from control and Pparγ BKO mice after rosiglitazone treatment stained with H&E. (g) Muscle Ucp3 mRNA expression in control and Pparγ BKO mice on HFD with or without rosiglitazone treatment (n = 5–10 per group). (h) Liver Ucp3 mRNA expression in control and Pparγ BKO mice on HFD or after rosiglitazone treatment (n = 5–10 per group). (a)–(c), data are shown as mean ± SEM. (d)–(h), all qPCR data shown are the fold induction of gene expression normalized with housekeeping gene and expressed as mean ± SEM. Statistical significance between control and Pparγ BKO mice, or between conditions connected by bars, is indicated by asterisks (p < 0.05), daggers (p < 0.01), or NS (not significant).
Fig. 4. Neuronal PPARγ is required for the full insulin–sensitizing effect of TZD treatment
(a) Intraperitoneal glucose tolerance tests (IPGTTs) on _Pparγ_f/f and BKO mice on HFD with or without rosiglitazone treatment for 7 wk (n = 6–12 per group). Statistical significance between values from rosiglitazone–treated control and Pparγ BKO mice indicated by asterisks (p < 0.05) and dagger (p < 0.01). (b)–(f), Hyperinsulinemic euglycemic clamp study on control and Pparγ BKO mice fed a HFD with or without rosiglitazone treatment for 8 wk (n = 7–12 per group). Glucose infusion rate (GIR) (b), insulin–stimulated glucose disposal rate (IS–GDR) (c), basal hepatic glucose production rate (basal HGP) (d), insulin–stimulated rate of HGP (e), and percent suppression of HGP by insulin (f) are shown. (g) Immunoblotting analysis of insulin-stimulated protein phosphorylation in liver extracts from control and BKO mice fed a HFD in the presence or absence of rosiglitazone treatment. (h) Quantification of relative phospho–protein levels normalized to respective total kinase protein content or β–tubulin. Data are shown as mean ± SEM. (i) Liver Pck1 (Pepck) mRNA expression in control and BKO mice fed a HFD or after rosiglitazone treatment (n = 5–10 per group). (j) Liver weight of control and Pparγ BKO mice (n = 10–14 per group) on HFD with or without rosiglitazone treatment. All data shown are as mean ± SEM. Statistical significance between conditions connected by bars is indicated by asterisks (p < 0.05), daggers (p < 0.01), or NS (no significance).
Comment in
- PPAR-γ action: it's all in your head.
Myers MG Jr, Burant CF. Myers MG Jr, et al. Nat Med. 2011 May;17(5):544-5. doi: 10.1038/nm0511-544. Nat Med. 2011. PMID: 21546969 No abstract available.
Similar articles
- Sex dimorphic actions of rosiglitazone in generalised peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-deficient mice.
Duan SZ, Usher MG, Foley EL 4th, Milstone DS, Brosius FC 3rd, Mortensen RM. Duan SZ, et al. Diabetologia. 2010 Jul;53(7):1493-505. doi: 10.1007/s00125-010-1748-2. Epub 2010 Apr 17. Diabetologia. 2010. PMID: 20401461 Free PMC article. - A role for central nervous system PPAR-γ in the regulation of energy balance.
Ryan KK, Li B, Grayson BE, Matter EK, Woods SC, Seeley RJ. Ryan KK, et al. Nat Med. 2011 May;17(5):623-6. doi: 10.1038/nm.2349. Epub 2011 May 1. Nat Med. 2011. PMID: 21532595 Free PMC article. - Obese mice lacking inducible nitric oxide synthase are sensitized to the metabolic actions of peroxisome proliferator-activated receptor-gamma agonism.
Dallaire P, Bellmann K, Laplante M, Gélinas S, Centeno-Baez C, Penfornis P, Peyot ML, Latour MG, Lamontagne J, Trujillo ME, Scherer PE, Prentki M, Deshaies Y, Marette A. Dallaire P, et al. Diabetes. 2008 Aug;57(8):1999-2011. doi: 10.2337/db08-0540. Epub 2008 May 5. Diabetes. 2008. PMID: 18458147 Free PMC article. - Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
Derosa G, Maffioli P. Derosa G, et al. Curr Mol Pharmacol. 2012 Jun;5(2):272-81. doi: 10.2174/1874467211205020272. Curr Mol Pharmacol. 2012. PMID: 22122457 Review. - Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone.
Simó R, Rodriguez A, Caveda E. Simó R, et al. Curr Drug Saf. 2010 Jul 2;5(3):234-44. doi: 10.2174/157488610791698352. Curr Drug Saf. 2010. PMID: 20210732 Review.
Cited by
- Immune dysregulation and macrophage polarization in peri-implantitis.
Li Y, Li X, Guo D, Meng L, Feng X, Zhang Y, Pan S. Li Y, et al. Front Bioeng Biotechnol. 2024 Jan 29;12:1291880. doi: 10.3389/fbioe.2024.1291880. eCollection 2024. Front Bioeng Biotechnol. 2024. PMID: 38347915 Free PMC article. Review. - Highlights from the Top 100 Most Influential Articles Regarding the Nuclear Receptor PPAR-γ: A Bibliometric Analysis.
Wu S, Dai H, Bai X, Wu Z, Wang X, Xiao B. Wu S, et al. Endocr Metab Immune Disord Drug Targets. 2024;24(11):1303-1314. doi: 10.2174/0118715303265935231114073638. Endocr Metab Immune Disord Drug Targets. 2024. PMID: 38317461 - Hypothalamic circuits and aging: keeping the circadian clock updated.
Vázquez-Lizarraga R, Mendoza-Viveros L, Cid-Castro C, Ruiz-Montoya S, Carreño-Vázquez E, Orozco-Solis R. Vázquez-Lizarraga R, et al. Neural Regen Res. 2024 Sep 1;19(9):1919-1928. doi: 10.4103/1673-5374.389624. Epub 2023 Dec 15. Neural Regen Res. 2024. PMID: 38227516 Free PMC article. - Identification of Crocetin as a Dual Agonist of GPR40 and GPR120 Responsible for the Antidiabetic Effect of Saffron.
Zhao X, Ahn D, Nam G, Kwon J, Song S, Kang MJ, Ahn H, Chung SJ. Zhao X, et al. Nutrients. 2023 Nov 13;15(22):4774. doi: 10.3390/nu15224774. Nutrients. 2023. PMID: 38004168 Free PMC article. - Assessing the multitargeted antidiabetic potential of three pomegranate peel-specific metabolites: An in silico and pharmacokinetics study.
Gull H, Ikram A, Khalil AA, Ahmed Z, Nemat A. Gull H, et al. Food Sci Nutr. 2023 Sep 13;11(11):7188-7205. doi: 10.1002/fsn3.3644. eCollection 2023 Nov. Food Sci Nutr. 2023. PMID: 37970376 Free PMC article.
References
- Hevener AL, et al. Muscle-specific Pparg deletion causes insulin resistance. Nature medicine. 2003;9:1491–1497. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U24 DK076126/DK/NIDDK NIH HHS/United States
- P30 CA23100/CA/NCI NIH HHS/United States
- R01 DK052989/DK/NIDDK NIH HHS/United States
- P30 CA023100/CA/NCI NIH HHS/United States
- P30 DK035816/DK/NIDDK NIH HHS/United States
- DK083042/DK/NIDDK NIH HHS/United States
- DK063491/DK/NIDDK NIH HHS/United States
- DK068384/DK/NIDDK NIH HHS/United States
- DK035816/DK/NIDDK NIH HHS/United States
- DK074868/DK/NIDDK NIH HHS/United States
- R01 DK090320/DK/NIDDK NIH HHS/United States
- DK033651/DK/NIDDK NIH HHS/United States
- F32 DK009062/DK/NIDDK NIH HHS/United States
- P01 DK074868/DK/NIDDK NIH HHS/United States
- R01 DK083042/DK/NIDDK NIH HHS/United States
- U54 HD012303-25/HD/NICHD NIH HHS/United States
- DK052989/DK/NIDDK NIH HHS/United States
- R01 DK033651/DK/NIDDK NIH HHS/United States
- DK09062/DK/NIDDK NIH HHS/United States
- P30 DK063491/DK/NIDDK NIH HHS/United States
- F32DK080604-01/DK/NIDDK NIH HHS/United States
- P01 DK068384/DK/NIDDK NIH HHS/United States
- P50 HD012303/HD/NICHD NIH HHS/United States
- F32 DK080604/DK/NIDDK NIH HHS/United States
- U54 HD012303/HD/NICHD NIH HHS/United States
- R37 DK033651/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials